Zhengdong Liang

EGFR:LGR5 bispecific antibody-drug conjugates show strong antitumor effects and outperform other ADCs in colorectal cancer models.

This study shows cetuximab increases LGR5 expression and improves the efficacy of LGR5-targeting ADCs in colorectal cancer models.

This study develops and tests a camptothecin analog conjugate targeting LGR4/5/6 in CRC models, showing potent anti-tumor activity with minimal toxicity.

This study develops and tests EREG-targeting ADCs showing efficacy in both RAS mutant and wildtype CRC, with high potency and safety in preclinical models.